Abstract
Iodinated contrast media (ICM) are extensively utilized in medical imaging to enhance tissue contrast, yet their impact on thyroid function has attracted increasing attention in recent years. ICM can induce thyroid dysfunction, with reported prevalence ranging from 1 to 15% and a higher incidence observed in individuals with pre-existing thyroid conditions or other risk factors like age, gender, underlying health issues, and repeated ICM exposure. This review summarized the classification of ICM and the potential mechanisms, risk assessment, and clinical management of ICM-induced thyroid dysfunction, especially in vulnerable populations such as pregnant women and elderly patients. Despite advancements that have enriched our understanding of the pathophysiology and treatment of ICM-induced thyroid dysfunction, critical knowledge gaps remain, such as the long-term effects of ICM on thyroid function, the dose-response relationship between ICM volume and thyroid dysfunction risk, and the ecological impacts of ICM. Therefore, further exploration of the underlying mechanisms of ICM-induced thyroid dysfunction and optimization of the management strategies will be crucial for the safe and effective use of ICM in clinical practice, and collaborative efforts between clinicians and researchers are essential to ensure that the risks of thyroid dysfunction do not outweigh the benefits of imaging.